Plain-English translation of NCT05183984 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding a medication called bevacizumab to and a newer drug called works better than using and alone for advanced ovarian cancer. Women who have had complete surgery to remove their cancer are randomly assigned to one of two treatment plans. The goal is to see which combination helps people live longer without their cancer coming back.
After surgery for advanced ovarian cancer, doctors need to find the best medication plan to prevent the cancer from returning. This trial is comparing two different approaches to see if adding bevacizumab to the standard treatment might give patients a better chance of staying cancer-free longer.
You likely qualify if…
You likely don't qualify if…
You will receive five cycles of given every 3 weeks, which you have already started. Then you will be randomly assigned to continue with either just the newer maintenance medication (taken by mouth daily for 2 years) or plus bevacizumab (an IV infusion every 3 weeks for 15 months, plus the daily pill for 2 years). You will have regular follow-up visits with blood tests and scans to monitor how you are doing, and your doctors will watch closely for any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
France